A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactome

Human Molecular Genetics

Volumn 24, Issue 24, 2015, Pages 7151-7158

  Didonna, Alessandro ^a   Isobe, Noriko ^a   Caillier, Stacy J ^a   Li, Kathy H ^a   Burlingame, Alma L ^a   Hauser, Stephen L ^a   Baranzini, Sergio E ^a   Patsopoulos, Nikolaos A ^b,c,d   Oksenberg, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHASE; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CYTOKINESIS; EVI5 GENE; GAIN OF FUNCTION MUTATION; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE MAPPING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HYDROPHOBICITY; IMMUNOPRECIPITATION; INSULATOR ELEMENT; LIPID METABOLISM; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; WILD TYPE; CHROMOSOMAL MAPPING; CHROMOSOME 1; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; RISK FACTOR;

EVI5 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEOME;

CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 1; HELA CELLS; HUMANS; MULTIPLE SCLEROSIS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOME; RISK FACTORS;

EID: 84952368198     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv412     Document Type: Article

References (58)

1. Ciccarelli, O., Barkhof, F., Bodini, B., De Stefano, N., Golay, X., Nicolay, K., Pelletier, D., Pouwels, P.J., Smith, S.A., Wheeler- Kingshott, C.A. et al. (2014) Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol., 13, 807-822.
2. Hauser, S.L. and Oksenberg, J.R. (2006) The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron, 52, 61-76.
3. Hauser, S.L., Chan, J.R. and Oksenberg, J.R. (2013) Multiple sclerosis: Prospects and promise. Ann. Neurol., 74, 317-327.
4. Oksenberg, J.R. (2013) Decoding multiple sclerosis: an update on genomics and future directions. Expert Rev. Neurother., 13, 11-19.
5. Oksenberg, J.R. and Barcellos, L.F. (2005)Multiple sclerosis genetics: leaving no stone unturned. Genes Immun., 6, 375-387.
6. International Multiple Sclerosis Genetics Consortium (2013) Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet., 45, 1353- 1360.
7. International Multiple Sclerosis Genetics Consortium (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med., 357, 851-862.
8. Hoppenbrouwers, I.A., Aulchenko, Y.S., Ebers, G.C., Ramagopalan, S.V., Oostra, B.A., van Duijn, C.M. and Hintzen, R.Q. (2008) EVI5 is a risk gene for multiple sclerosis. Genes Immun., 9, 334-337.
9. Johnson, B.A., Wang, J., Taylor, E.M., Caillier, S.J., Herbert, J., Khan, O.A., Cross, A.H., De Jager, P.L., Gourraud, P.A., Cree, B.C. et al. (2010) Multiple sclerosis susceptibility alleles in African Americans. Genes Immun., 11, 343-350.
10. Alcina, A., Fernandez, O., Gonzalez, J.R., Catala-Rabasa, A., Fedetz, M., Ndagire, D., Leyva, L., Guerrero, M., Arnal, C., Delgado, C. et al. (2010) Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus formultiple sclerosis. Eur. J. Hum. Genet., 18, 827-831.
11. International Multiple Sclerosis Genetics Consortium and Wellcome Trust Case Control Consortium (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 476, 214-219.
12. Martin, D., Pantoja, C., Fernandez Minan, A., Valdes-Quezada, C., Molto, E., Matesanz, F., Bogdanovic, O., de la Calle-Mustienes, E., Dominguez, O., Taher, L. et al. (2011) Genomewide CTCF distribution in vertebrates defines equivalent sites that aid the identification of disease-associated genes. Nat. Struct. Mol. Biol., 18, 708-714.
13. Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature, 467, 1061-1073.
14. Isobe, N., Madireddy, L., Khankhanian, P., Matsushita, T., Caillier, S.J., More, J.M., Gourraud, P.A., McCauley, J.L., Beecham, A.H., International Multiple Sclerosis Genetics Consortium et al. (2015) An ImmunoChip study of multiple sclerosis risk in African Americans. Brain, 138, 1518-1530.
15. Lim, Y.S. and Tang, B.L. (2013) The Evi5 family in cellular physiology and pathology. FEBS Lett., 587, 1703-1710.
16. Frasa, M.A., Koessmeier, K.T., Ahmadian, M.R. and Braga, V. M. (2012) Illuminating the functional and structural repertoire of human TBC/RABGAPs. Nat. Rev. Mol. Cell Biol., 13, 67-73.
17. Hirano, T. (2006) At the heart of the chromosome: SMC proteins in action. Nat. Rev. Mol. Cell Biol., 7, 311-322.
18. Eldridge, A.G., Loktev, A.V., Hansen, D.V., Verschuren, E.W., Reimann, J.D. and Jackson, P.K. (2006) The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphasepromoting complex inhibitor emi1. Cell, 124, 367-380.
19. Faitar, S.L., Sossey-Alaoui, K., Ranalli, T.A. and Cowell, J.K. (2006) EVI5 protein associates with the INCENP-aurora B kinase-survivin chromosomal passenger complex and is involved in the completion of cytokinesis. Exp. Cell Res., 312, 2325-2335.
20. Westlake, C.J., Junutula, J.R., Simon, G.C., Pilli, M., Prekeris, R., Scheller, R.H., Jackson, P.K. and Eldridge, A.G. (2007) Identification of Rab11 as a small GTPase binding protein for the Evi5 oncogene. Proc. Natl Acad. Sci. USA, 104, 1236-1241.
21. Dabbeekeh, J.T., Faitar, S.L., Dufresne, C.P. and Cowell, J.K. (2007) The EVI5 TBC domain provides the GTPase-activating protein motif for RAB11. Oncogene, 26, 2804-2808.
22. Strauss, H.M. and Keller, S. (2008) Pharmacological interference with protein-protein interactions mediated by coiledcoil motifs. Handb. Exp. Pharmacol., 186, 461-482.
23. Kocher, T. and Superti-Furga, G. (2007) Mass spectrometrybased functional proteomics: from molecular machines to protein networks. Nat. Methods, 4, 807-815.
24. Faitar, S.L., Dabbeekeh, J.T., Ranalli, T.A. and Cowell, J.K. (2005) EVI5 is a novel centrosomal protein that binds to alpha- and gamma-tubulin. Genomics, 86, 594-605.
25. Stenmark, H. (2009) Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol., 10, 513-525.
26. Hutagalung, A.H. and Novick, P.J. (2011) Role of Rab GTPases in membrane traffic and cell physiology. Physiol. Rev., 91, 119-149.
27. Itoh, T., Satoh, M., Kanno, E. and Fukuda, M. (2006) Screening for target Rabs of TBC (Tre-2/Bub2/Cdc16) domain-containing proteins based on their Rab-binding activity. Genes Cells, 11, 1023-1037.
28. Laflamme, C., Assaker, G., Ramel, D., Dorn, J.F., She, D., Maddox, P.S. and Emery, G. (2012) Evi5 promotes collective cell migration through its Rab-GAP activity. J. Cell Biol., 198, 57-67.
29. Johnson, D.R., Biedermann, B.C. and Mook-Kanamori, B. (2000) Rapid cloning of HLA class I cDNAs by locus specific PCR. J. Immunol. Methods, 233, 119-129.
30. Trowsdale, J. and Knight, J.C. (2013) Major histocompatibility complex genomics and human disease. Annu. Rev. Genomics Hum. Genet., 14, 301-323.
31. Boyle, L.H., Gillingham, A.K., Munro, S. and Trowsdale, J. (2006) Selective export of HLA-F by its cytoplasmic tail. J. Immunol., 176, 6464-6472.
32. Fogdell-Hahn, A., Ligers, A., Gronning, M., Hillert, J. and Olerup, O. (2000) Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens, 55, 140-148.
33. Friese, M.A., Jakobsen, K.B., Friis, L., Etzensperger, R., Craner, M.J., McMahon, R.M., Jensen, L.T., Huygelen, V., Jones, E.Y., Bell, J.I. et al. (2008) Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat. Med., 14, 1227-1235.
34. Patsopoulos, N.A., Barcellos, L.F., Hintzen, R.Q., Schaefer, C., van Duijn, C.M., Noble, J.A., Raj, T., International Multiple Sclerosis Genetics Consortium, ANZgene Consortium, Gourraud, P.A. et al. (2013) Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLOS Genet., 9, e1003926.
35. ANZgene Consortium (2009) Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet., 41, 824-828.
36. Wheeler, D., Bandaru, V.V., Calabresi, P.A., Nath, A. and Haughey, N.J. (2008) A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain, 131, 3092-3102.
37. Carlson, N.G. and Rose, J.W. (2006) Antioxidants in multiple sclerosis: do they have a role in therapy? CNS Drugs, 20, 433-441.
38. Ohler, B., Graf, K., Bragg, R., Lemons, T., Coe, R., Genain, C., Israelachvili, J. and Husted, C. (2004) Role of lipid interactions in autoimmune demyelination. Biochim. Biophys. Acta, 1688, 10-17.
39. Cyster, J.G. and Schwab, S.R. (2012) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol., 30, 69-94.
40. Schwab, S.R., Pereira, J.P., Matloubian, M., Xu, Y., Huang, Y. and Cyster, J.G. (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science, 309, 1735-1739.
41. Bagdanoff, J.T., Donoviel, M.S., Nouraldeen, A., Tarver, J., Fu, Q., Carlsen, M., Jessop, T.C., Zhang, H., Hazelwood, J., Nguyen, H. et al. (2009) Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J. Med. Chem., 52, 3941-3953.
42. Chi, H. (2011) Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol. Sci., 32, 16-24.
43. Billich, A., Baumruker, T., Beerli, C., Bigaud, M., Bruns, C., Calzascia, T., Isken, A., Kinzel, B., Loetscher, E., Metzler, B. et al. (2013) Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis. PLOS ONE, 8, e59630.
44. Weiler, S., Braendlin, N., Beerli, C., Bergsdorf, C., Schubart, A., Srinivas, H., Oberhauser, B. and Billich, A. (2014) Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin- 1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis. J. Med. Chem., 57, 5074-5084.
45. Kappos, L., Radue, E.W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang- Auberson, L. et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med., 362, 387-401.
46. Didonna, A. and Oksenberg, J.R. (2015) Genetic determinants of risk and progression in multiple sclerosis. Clin. Chim. Acta, 449, 16-22.
47. Holaska, J.M. and Wilson, K.L. (2007) An emerin "proteome": purification of distinct emerin-containing complexes from HeLa cells suggests molecular basis for diverse roles including gene regulation, mRNA splicing, signaling, mechanosensing, and nuclear architecture. Biochemistry, 46, 8897-8908.
48. Isabelle, M., Moreel, X., Gagne, J.P., Rouleau, M., Ethier, C., Gagne, P., Hendzel, M.J. and Poirier, G.G. (2010) Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry. Proteome Sci., 8, 22.
49. Patsopoulos, N.A., Bayer Pharma MS GeneticsWorking Group, Steering Committees of Studies Evaluating IFNß-1b and CCR1- Antagonist, ANZgene Consortium, GeneMSA, International Multiple Sclerosis Genetics Consortium and de Bakker, P.I.W. (2011) Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann. Neurol., 70, 897-912.
50. Browning, S.R. and Browning, B.L. (2007) Rapid and accurate haplotype phasing and missing-data inference for wholegenome association studies by use of localized haplotype clustering. Am. J. Hum. Genet., 81, 1084-1097.
51. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J. et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet., 81, 559-575.
52. Ward, L.D. and Kellis, M. (2012) HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucl. Acid Res., 40, D930-D934.
53. Guan, S., Price, J.C., Prusiner, S.B., Ghaemmaghami, S. and Burlingame, A.L. (2011) A data processing pipeline for mammalian proteome dynamics studies using stable isotopemetabolic labeling. Mol. Cell Proteomics, 10, M111010728.
54. Bedia, C., Camacho, L., Casas, J., Abad, J.L., Delgado, A., Van Veldhoven, P.P. and Fabrias, G. (2009) Synthesis of a fluorogenic analogue of sphingosine-1-phosphate and its use to determine sphingosine-1-phosphate lyase activity. Chembiochem, 10, 820-822.
55. Carbon, S., Ireland, A., Mungall, C.J., Shu, S., Marshall, B., Lewis, S. and Ami, G.O.H. and Web Presence Working, G. (2009) AmiGO: online access to ontology and annotation data. Bioinformatics, 25, 288-289.
56. Kelley, L.A. and Sternberg, M.J. (2009) Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc., 4, 363-371.
57. Porollo, A. and Meller, J. (2007) Versatile annotation and publication quality visualization of protein complexes using POLYVIEW-3D. BMC Bioinformatics, 8, 316.
58. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B. and Ideker, T. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res., 13, 2498-2504.